Traws Pharma Overview
- Year Founded
-
2021
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
TRAW
- Investments
-
1
- Share Price
-
$0.24
- (As of Wednesday Closing)
Traws Pharma General Information
Description
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Contact Information
Website
www.trawspharma.comCorporate Office
- 12 Penns Trail
- Newtown, PA 18940
- United States
Corporate Office
- 12 Penns Trail
- Newtown, PA 18940
- United States
Traws Pharma Timeline
Traws Pharma Stock Performance
As of 18-Nov-2026, Traws Pharma’s stock price is $0.24. Its current market cap is $3.73M with 15.4M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.24 | $0.23 | $0.22 - $3.23 | $3.73M | 15.4M | 610K | -$1.71 |
Traws Pharma Financials Summary
As of 30-Jun-2026, Traws Pharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,644 | 2,610 | 21,457 | (9,584) |
| Revenue | 0 | 2,790 | 226 | 226 |
| EBITDA | (21,419) | 9,231 | (166,511) | (18,932) |
| Net Income | (21,566) | 9,170 | (166,523) | (18,948) |
| Total Assets | 11,470 | 10,617 | 24,962 | 22,683 |
| Total Debt | 0 | 0 | 0 | 0 |
Traws Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Traws Pharma Patents
Traws Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026122604-A1 | Synthesis of (1r,2s,5s)-n-[(1s)-1-cyano-2-(2-oxoindolin-3-yl)ethyl]-3-[(2s)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | Pending | 02-Dec-2024 | ||
| JP-2025520539-A | Compounds for the treatment of coronavirus infections | Pending | 17-Jun-2022 | ||
| JP-2025520541-A | Compounds for the treatment of coronavirus infections | Pending | 17-Jun-2022 | ||
| AU-2023293272-A1 | Compounds for treatment a coronavirus infection | Active | 17-Jun-2022 | ||
| AU-2023293272-B2 | Compounds for treatment a coronavirus infection | Active | 17-Jun-2022 | C07K5/06034 |
Traws Pharma Signals
Traws Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Traws Pharma Acquisitions (1)
Traws Pharma’s most recent deal was a Merger/Acquisition with Onconova Therapeutics. The deal was made on 01-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Onconova Therapeutics | 01-Apr-2024 | Merger/Acquisition | Biotechnology |
Traws Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.97 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Traws Pharma FAQs
-
When was Traws Pharma founded?
Traws Pharma was founded in 2021.
-
Where is Traws Pharma headquartered?
Traws Pharma is headquartered in Newtown, PA.
-
What is the size of Traws Pharma?
Traws Pharma has 7 total employees.
-
What industry is Traws Pharma in?
Traws Pharma’s primary industry is Drug Discovery.
-
Is Traws Pharma a private or public company?
Traws Pharma is a Public company.
-
What is Traws Pharma’s stock symbol?
The ticker symbol for Traws Pharma is TRAW.
-
What is the current stock price of Traws Pharma?
As of 18-Nov-2026 the stock price of Traws Pharma is $0.24.
-
What is the current market cap of Traws Pharma?
The current market capitalization of Traws Pharma is $3.73M.
-
What is Traws Pharma’s annual earnings per share (EPS)?
Traws Pharma’s EPS for 12 months was -$1.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process